ADC Therapeutics SA financial data

Symbol
ADCT on NYSE
Industry
Pharmaceutical Preparations
Location
Biopole, Route De La Corniche 3 B, Epalinges, Switzerland
State of incorporation
Switzerland
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96.6M shares
Common Stock, Shares, Outstanding 96.5M shares
Entity Public Float 153M USD
Common Stock, Value, Issued 8.23M USD
Weighted Average Number of Shares Outstanding, Basic 95.7M shares +17.5%
Weighted Average Number of Shares Outstanding, Diluted 95.7M shares +17.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 17.4M USD -9.71%
Revenue from Contract with Customer, Excluding Assessed Tax 17M USD -11.3%
Research and Development Expense 107M USD -33.2%
Selling and Marketing Expense 10.7M USD -26%
General and Administrative Expense 43.2M USD -29.9%
Costs and Expenses 46.5M USD -21.2%
Operating Income (Loss) -29M USD +26.8%
Nonoperating Income (Expense) -28M USD +48.7%
Income Tax Expense (Benefit) 234K USD
Net Income (Loss) Attributable to Parent -36.5M USD +25.3%
Earnings Per Share, Basic -0.38 USD/shares +36.7%
Earnings Per Share, Diluted -0.38 USD/shares +36.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 300M USD
Inventory, Net 15.2M USD
Assets, Current 355M USD
Deferred Income Tax Assets, Net 0 USD -100%
Property, Plant and Equipment, Net 5.48M USD
Operating Lease, Right-of-Use Asset 9.69M USD
Other Assets, Noncurrent 992K USD
Assets 372M USD -26.7%
Accounts Payable, Current 10.7M USD
Accrued Liabilities, Current 46.9M USD
Liabilities, Current 57.6M USD
Deferred Income Tax Liabilities, Net 1.33M USD -66.7%
Operating Lease, Liability, Noncurrent 9.31M USD
Other Liabilities, Noncurrent 6.62M USD
Liabilities 503M USD -2.41%
Accumulated Other Comprehensive Income (Loss), Net of Tax -338K USD
Retained Earnings (Accumulated Deficit) -1.42B USD
Stockholders' Equity Attributable to Parent -132M USD -569%
Liabilities and Equity 372M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44.1M USD -186%
Net Cash Provided by (Used in) Financing Activities 356K USD -16.2%
Net Cash Provided by (Used in) Investing Activities -531K USD +47.7%
Common Stock, Shares, Issued 99.5M shares
Common Stock, Par or Stated Value Per Share 0.08 CHF/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 300M USD -13.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.9M USD +5.01%
Deferred Tax Assets, Valuation Allowance 212M USD +61.7%
Deferred Tax Assets, Gross 213M USD +23.9%
Operating Lease, Liability 11.6M USD
Depreciation 326K USD +19.4%
Payments to Acquire Property, Plant, and Equipment 531K USD -47.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.7M USD +25.5%
Lessee, Operating Lease, Liability, to be Paid 13.7M USD
Property, Plant and Equipment, Gross 10.2M USD
Operating Lease, Liability, Current 1.42M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.94M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.96M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure +76.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.01M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.98M USD
Deferred Tax Assets, Operating Loss Carryforwards 163M USD +24.2%
Unrecognized Tax Benefits 6.62M USD +27.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.99M USD
Additional Paid in Capital 1.28B USD
Deferred Tax Assets, Net of Valuation Allowance 1.33M USD -96.8%
Interest Expense 12.7M USD +23%